India’s stock regulators say they're examining a whistleblower complaint against top domestic drugmaker Sun Pharma.
The Chinese API maker at the heart of a global scare and recall of blood pressure medicines has been savaged in an FDA warning letter.
CDMO Lonza is joining a rush of companies looking to cash in on China's eases drug regulations by building a biologics facility there.
The Takeda-Shire deal passes investors; Sun suffers from a long list of allegations; J&J and Legend update CAR-T data.
Of 31 drugs the Chinese government listed for a pilot bidding program, multinational pharmas landed only two contracts.
The deal will make Takeda "a more competitive, agile, highly profitable, and therefore more resilient company," said CEO Christophe Weber.
Though managing director Dilip Shanghvi tried to allay investors' concerns, a couple of key questions remain unanswered.
A Chinese maker of heparin and APIs for oncology and other drugs is investing nearly $150 million as it targets innovative drugs for China.
Litigation is growing over tainted blood pressure medications with a class-action lawsuit now filed in Florida against Walmart and three drug companies that…
The Justice Department will no longer pursue a whistleblower case against Gilead for using an unapproved API in some HIV drugs.